ArticleAntiviral research2014
Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative.
Article in Antiviral research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Uncovering the Potent Antiviral Activity of the Sesterterpenoids from the Sponge Ircinia Felix Against Human Adenoviruses: from the Natural Source to the Total Synthesis.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Current antiviral agents against human adenoviruses associated with respiratory infections.Frontiers in pediatrics · 2024Review
- In Vitro efficacy of cyclosporine a and various antiseptics and antiviral drugs on adenovirus genotype 8, a common cause of epidemic keratoconjunctivitis.International ophthalmology · 2023Article
- Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone.Frontiers in pharmacology · 2023Article
- Ribose conversion with amino acids into pyrraline platform chemicals - expeditious synthesis of diverse pyrrole-fused alkaloid compounds.RSC advances · 2021Article
- Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies.Antiviral research · 2021Review
- Discovery of a Small Molecule Inhibitor of Human Adenovirus Capable of Preventing Escape from the Endosome.International journal of molecular sciences · 2021Article
- Antiviral Effects of Curcumin on Adenovirus Replication.Microorganisms · 2020Article
- Recent Advances in Novel Antiviral Therapies against Human Adenovirus.Microorganisms · 2020Review
- Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.Scientific reports · 2019Article
- A single point mutation in precursor protein VI doubles the mechanical strength of human adenovirus.Journal of biological physics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The number of disseminated adenovirus (Ad) infections continues to increase mostly due to the growing use of immunosuppressive treatments. Recipients of solid organ or hematopoietic stem cell transplants, mainly in pediatric units, exhibit a high morbidity and mortality due to these infections. Unfortunately, there are no Ad-specific antiviral drugs currently approved for medical use. To address this situation, we used high-throughput screening (HTS) of synthetic small molecule libraries to identify compounds that restrict Ad infection. Among the more than 25,000 compounds screened, we identified a hit compound that significantly inhibited Ad infection. The compound (15D8) is a trisubstituted piperazin-2-one derivative that showed substantial antiviral activity with little or no cytotoxicity at low micromolar concentrations. Compound 15D8 selectively inhibits Ad DNA replication in the nucleus, providing a potential candidate for the development of a new class of antiviral compounds to treat Ad infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.